Clinical Evaluation under SAHPGL-MD-16 for South African Medical Device Registration

1. Key takeaways

South Africa’s clinical evaluation requirements are governed by the SAHPGL-MD-16 Clinical Evaluation guidance, which is one of the core evidence modules of the registration dossier. Regulation 8(5)(b)(vii) requires the registration application form to state the name and physical address of the clinical investigation site (where applicable), showing that clinical data, including local clinical investigations, is a formal field on the application form. The evidence hierarchy follows the internationally common structure: clinical literature and clinical data on equivalent devices come first, and a clinical trial is required only where the existing evidence is insufficient to confirm safety and effectiveness. Evidence expectations are markedly higher for Class C and Class D devices, implantable devices, and the clinical performance studies of IVDs. Two further points deserve attention. First, the distinction between clinical evaluation and clinical trials is a general-versus-exception relationship, which directly shapes the cost structure of the programme: products that can be evaluated through equivalence and literature avoid the time and expense of local trials. Second, under the reliance pathway, SAHPGL-MD-22 allows clinical evidence accepted by reference regulatory authorities to be taken into account, but the applicability of that evidence to South African populations, disease profiles and use environments still needs to be argued in the dossier.

2. Legal basis

3. Expert insights

Insight 1: Clinical evaluation and clinical trials stand in a general-versus-exception relationship. The common structure is: first attempt to complete the evaluation using clinical literature and clinical data on equivalent devices; only where the existing evidence is insufficient to confirm safety and effectiveness is a clinical trial required. This order determines the cost structure. A product whose evaluation can be completed through equivalence comparison saves the time and expense of local clinical trials, while a product that cannot must budget for study design, ethics approval and site work under Regulation 16. Companies should therefore test the equivalence route seriously before conceding that a trial is needed, and should document why the literature route was or was not sufficient.

Insight 2: Regulation 8(5)(b)(vii) makes the clinical investigation site a mandatory field on the application form. The provision requires the application to state the name and physical address of the clinical investigation site (where applicable). This shows that SAHPRA attends to the source sites of clinical data already at the application stage, and it reserves an interface for potential inspections of development and manufacturing sites. Companies should ensure that what is entered on the form is consistent with the clinical investigation records, because a mismatch between the declared site and the study documentation is an easily avoidable deficiency that invites questions about data integrity.

Insight 3: Class C and Class D carry the main burden of clinical evidence. The higher the classification, the greater the depth and independence required of the clinical evaluation. The 2026 Phase 2 feasibility study focuses expressly on Class C and Class D, which confirms the same point from the regulator’s side. Practical estimate: high-risk products should have their clinical evidence planned early, rather than being started after the call for registration is published. For these classes, evidence generation has the longest lead time of any dossier module, and a late start is the most common reason programmes slip.

Insight 4: The core of clinical evaluation for IVDs is clinical performance, not therapeutic effect. For an IVD, what is evaluated is the ability of the test to produce correct results in the target population and setting of use, involving clinical concordance, sensitivity, specificity and expected values. This is a separate metric system from clinical evaluation for non-IVD devices, and companies preparing dossiers for several markets in one effort should take particular care to keep the two structures apart. An IVD section written in device-trial language, or a device section written in diagnostic-performance language, signals that the author has not engaged with the applicable guide.

Insight 5: Under the reliance pathway, foreign clinical evidence can be accepted, but its applicability must be argued. SAHPGL-MD-22 allows reliance on the assessments of reference authorities while reserving the right to ask follow-up questions. Practical estimate: when citing foreign clinical data, argue at the same time the relevance to South Africa of population characteristics, disease profiles and the use environment, which is a common focus of African market reviews, for example the local spectrum of circulating pathogens and co-infection patterns. Evidence that is persuasive in its country of origin but unconnected to South African conditions will draw questions that a short bridging analysis could have pre-empted.

4. Practical recommendations

1. Assess the feasibility of equivalence comparison first: prefer the literature and existing data route where it can support the evaluation.
2. Plan clinical evidence early for high-risk products: Class C and Class D in particular.
3. Organise IVD evidence per the clinical performance metric system: do not apply the non-IVD structure.
4. When citing foreign data, argue local applicability: population, disease profile, use environment.
5. Keep clinical investigation site information consistent with the application form: Regulation 8(5)(b)(vii).
6. Update the clinical evaluation report continuously with post-market data, closing the loop with post-market surveillance.

5. Verification checklist

• □ The current version of SAHPGL-MD-16 has been obtained
• □ It has been assessed whether equivalent-device clinical literature and data suffice to complete the evaluation
• □ Where insufficient, the clinical trial pathway has been planned
• □ IVD evidence has been organised per the clinical performance metric system
• □ The South African local applicability of foreign clinical data has been argued
• □ The name and address of the clinical investigation site have been reported per Regulation 8(5)(b)(vii)
• □ The depth of evidence has been confirmed according to the product classification (Class C/D)
• □ A continuous update mechanism for the clinical evaluation report has been established

Regulatory information verified as of 29 October 2026. The regulations, guidance documents and effective dates described in this article are limited to the official sources listed under Legal basis as published on that date; where official documents are subsequently updated, the latest published version prevails.

• South Africa local resources: GRZAN assists manufacturers from the Chinese mainland and overseas with SAHPRA medical device establishment licence (MDEL) applications and product registration preparation, including authorised representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical dossier preparation, and the setup of vigilance and adverse event reporting mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A/B/C/D), establishment licence applications and renewals, reliance pathway justification, technical dossier and Essential Principles conformity argumentation, labelling and IFU localisation in English, and support for post-market vigilance and annual compliance information submissions.
• Contact: info@grzanglobal.com; hito.lin@grzan.cn; website www.grzan.cn.